Teladoc (TDOC) Stock Forecast & Price Target

Compare

12,084 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

TDOC Analyst Ratings

Moderate Buy

7 Buy

15 Hold

0 Sell

Based on 22 analysts giving stock ratings to

Teladoc

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

TDOC Stock 12 Month Forecast

Average Price Target

$7.21

▲(34.26% Upside)

Based on 22 Wall Street analysts offering 12 month price targets for Teladoc in the last 3 months. The average price target is $7.21 with a high forecast of $11.00 and a low forecast of $5.00. The average price target represents a 34.26% change from the last price of $5.37.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","6":"$6","8":"$8","10":"$10","12":"$12"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$11.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.21,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$7.21</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,6,8,10,12],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.16,5.609230769230769,6.058461538461539,6.507692307692308,6.956923076923077,7.406153846153846,7.855384615384615,8.304615384615385,8.753846153846155,9.203076923076923,9.652307692307692,10.10153846153846,10.55076923076923,{"y":11,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.16,5.317692307692308,5.475384615384615,5.633076923076923,5.7907692307692304,5.9484615384615385,6.1061538461538465,6.2638461538461545,6.421538461538462,6.579230769230769,6.736923076923077,6.894615384615385,7.052307692307693,{"y":7.21,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.16,5.147692307692308,5.135384615384615,5.1230769230769235,5.110769230769231,5.098461538461539,5.086153846153846,5.073846153846154,5.061538461538461,5.049230769230769,5.036923076923077,5.024615384615385,5.012307692307692,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.56,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 35, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.76,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.99,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.87,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.58,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 41, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.94,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.64,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 48, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.8,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 81, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.63,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 90, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.44,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 74, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 51, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.37,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 90, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.16,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 92, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$11.00

Average Price Target$7.21

Lowest Price Target$5.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Lisa Gill

J.P. Morgan

$9→$7

Hold

30.35%

Upside

Assigned

03/13/26

J.P. Morgan Releases a Hold Rating on Teladoc (TDOC)

Jailendra Singh

Truist Financial

―

Hold

―

Reiterated

03/12/26

Analysts Offer Insights on Healthcare Companies: Upstream Bio, Inc. (NASDAQ: UPB), TScan Therapeutics (NASDAQ: TCRX) and Teladoc (NYSE: TDOC)

George Hill

Deutsche Bank

$11

Buy

104.84%

Upside

Upgraded

03/10/26

Teladoc upgraded to Buy from Hold at Deutsche BankTeladoc upgraded to Buy from Hold at Deutsche Bank

David Larsen

BTIG

―

Hold

―

Reiterated

03/10/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Dyne Therapeutics (NASDAQ: DYN), Biohaven Ltd. (NYSE: BHVN) and Teladoc (NYSE: TDOC)

Michael Wiederhorn

Oppenheimer

$12→$7

Buy

30.35%

Upside

Reiterated

03/03/26

Teladoc price target lowered to $7 from $12 at OppenheimerTeladoc price target lowered to $7 from $12 at Oppenheimer

Daniel Grosslight

Citi

$9→$6

Hold

11.73%

Upside

Reiterated

03/03/26

Teladoc price target lowered to $6 from $9 at CitiTeladoc price target lowered to $6 from $9 at Citi

Kevin Caliendo

UBS

$9→$6

Hold

11.73%

Upside

Reiterated

02/27/26

Analysts Offer Insights on Healthcare Companies: Teladoc (NYSE: TDOC), Intellia Therapeutics (NASDAQ: NTLA) and Structure Therapeutics, Inc. Sponsored ADR (NASDAQ: GPCR)

David Roman

Goldman Sachs

$8→$7

Buy

30.35%

Upside

Reiterated

02/27/26

Teladoc price target lowered to $7 from $8 at Goldman SachsTeladoc price target lowered to $7 from $8 at Goldman Sachs

Scott Schoenhaus

KeyBanc

―

Hold

―

Reiterated

02/27/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Teladoc (NYSE: TDOC) and Progyny (NASDAQ: PGNY)

Allen Lutz

Bank of America Securities

Buy

30.35%

Upside

Upgraded

02/26/26

Teladoc upgraded to Buy from Neutral at BofATeladoc upgraded to Buy from Neutral at BofA

Richard Close

Canaccord Genuity

$12→$10

Buy

86.22%

Upside

Reiterated

02/26/26

Teladoc price target lowered to $10 from $12 at CanaccordTeladoc price target lowered to $10 from $12 at Canaccord

Charles Rhyee

TD Cowen

$8→$6

Hold

11.73%

Upside

Assigned

02/26/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Teladoc (NYSE: TDOC), Alkermes (NASDAQ: ALKS) and Lemaitre Vascular (NASDAQ: LMAT)

David Grossman

Stifel Nicolaus

$8→$6

Hold

11.73%

Upside

Reiterated

02/26/26

Teladoc price target lowered to $6 from $8 at StifelTeladoc price target lowered to $6 from $8 at Stifel

Steven Valiquette

Mizuho Securities

$10→$6

Hold

11.73%

Upside

Reiterated

02/26/26

Teladoc price target lowered to $6 from $10 at MizuhoTeladoc price target lowered to $6 from $10 at Mizuho

Peter Warendorf

Barclays

$8.5

Hold

58.29%

Upside

Reiterated

02/26/26

Teladoc (TDOC) Receives a Hold from Barclays

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Lisa Gill

J.P. Morgan

$9→$7

Hold

30.35%

Upside

Assigned

03/13/26

J.P. Morgan Releases a Hold Rating on Teladoc (TDOC)

Jailendra Singh

Truist Financial

―

Hold

―

Reiterated

03/12/26

Analysts Offer Insights on Healthcare Companies: Upstream Bio, Inc. (NASDAQ: UPB), TScan Therapeutics (NASDAQ: TCRX) and Teladoc (NYSE: TDOC)

George Hill

Deutsche Bank

$11

Buy

104.84%

Upside

Upgraded

03/10/26

Teladoc upgraded to Buy from Hold at Deutsche BankTeladoc upgraded to Buy from Hold at Deutsche Bank

David Larsen

BTIG

―

Hold

―

Reiterated

03/10/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Dyne Therapeutics (NASDAQ: DYN), Biohaven Ltd. (NYSE: BHVN) and Teladoc (NYSE: TDOC)

Michael Wiederhorn

Oppenheimer

$12→$7

Buy

30.35%

Upside

Reiterated

03/03/26

Teladoc price target lowered to $7 from $12 at OppenheimerTeladoc price target lowered to $7 from $12 at Oppenheimer

Daniel Grosslight

Citi

$9→$6

Hold

11.73%

Upside

Reiterated

03/03/26

Teladoc price target lowered to $6 from $9 at CitiTeladoc price target lowered to $6 from $9 at Citi

Kevin Caliendo

UBS

$9→$6

Hold

11.73%

Upside

Reiterated

02/27/26

Analysts Offer Insights on Healthcare Companies: Teladoc (NYSE: TDOC), Intellia Therapeutics (NASDAQ: NTLA) and Structure Therapeutics, Inc. Sponsored ADR (NASDAQ: GPCR)

David Roman

Goldman Sachs

$8→$7

Buy

30.35%

Upside

Reiterated

02/27/26

Teladoc price target lowered to $7 from $8 at Goldman SachsTeladoc price target lowered to $7 from $8 at Goldman Sachs

Scott Schoenhaus

KeyBanc

―

Hold

―

Reiterated

02/27/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Teladoc (NYSE: TDOC) and Progyny (NASDAQ: PGNY)

Allen Lutz

Bank of America Securities

Buy

30.35%

Upside

Upgraded

02/26/26

Teladoc upgraded to Buy from Neutral at BofATeladoc upgraded to Buy from Neutral at BofA

Richard Close

Canaccord Genuity

$12→$10

Buy

86.22%

Upside

Reiterated

02/26/26

Teladoc price target lowered to $10 from $12 at CanaccordTeladoc price target lowered to $10 from $12 at Canaccord

Charles Rhyee

TD Cowen

$8→$6

Hold

11.73%

Upside

Assigned

02/26/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Teladoc (NYSE: TDOC), Alkermes (NASDAQ: ALKS) and Lemaitre Vascular (NASDAQ: LMAT)

David Grossman

Stifel Nicolaus

$8→$6

Hold

11.73%

Upside

Reiterated

02/26/26

Teladoc price target lowered to $6 from $8 at StifelTeladoc price target lowered to $6 from $8 at Stifel

Steven Valiquette

Mizuho Securities

$10→$6

Hold

11.73%

Upside

Reiterated

02/26/26

Teladoc price target lowered to $6 from $10 at MizuhoTeladoc price target lowered to $6 from $10 at Mizuho

Peter Warendorf

Barclays

$8.5

Hold

58.29%

Upside

Reiterated

02/26/26

Teladoc (TDOC) Receives a Hold from Barclays

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Teladoc

3 Months

xxx

Success Rate

26/48 ratings generated profit

Average Return

+0.55%

reiterated a xxx

rating 19 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 54.17% of your transactions generating a profit, with an average return of +0.55% per trade.

1 Year

Richard CloseCanaccord Genuity

Success Rate

22/48 ratings generated profit

Average Return

+11.33%

reiterated a buy rating 19 days ago

Copying Richard Close's trades and holding each position for 1 Year would result in 45.83% of your transactions generating a profit, with an average return of +11.33% per trade.

2 Years

xxx

Success Rate

10/21 ratings generated profit

Average Return

+36.36%

upgraded a xxx

rating 7 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 47.62% of your transactions generating a profit, with an average return of +36.36% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TDOC Analyst Recommendation Trends

Rating

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

101

In the current month, TDOC has received 9 Buy Ratings, 92 Hold Ratings, and 0 Sell Ratings. TDOC average Analyst price target in the past 3 months is 7.21.

Each month's total comprises the sum of three months' worth of ratings.

TDOC Financial Forecast

TDOC Earnings Forecast

Next quarter’s earnings estimate for TDOC is -$0.34 with a range of -$0.40 to -$0.24. The previous quarter’s EPS was -$0.14. TDOC beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year TDOC has Performed in-line its overall industry.

TDOC Sales Forecast

Next quarter’s sales forecast for TDOC is $613.82M with a range of $604.38M to $650.40M. The previous quarter’s sales results were $642.27M. TDOC beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year TDOC has Performed in-line its overall industry.

TDOC Stock Forecast FAQ

What is TDOC’s average 12-month price target, according to analysts?

Based on analyst ratings, Teladoc’s 12-month average price target is 7.21.

What is TDOC’s upside potential, based on the analysts’ average price target?

Teladoc has 34.26% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is TDOC a Buy, Sell or Hold?

Teladoc has a consensus rating of Moderate Buy which is based on 7 buy ratings, 15 hold ratings and 0 sell ratings.

What is Teladoc’s price target?

The average price target for Teladoc is 7.21. This is based on 22 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $11.00 ,the lowest forecast is $5.00. The average price target represents 34.26% Increase from the current price of $5.37.

What do analysts say about Teladoc?

Teladoc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 22 Wall Streets Analysts.

How can I buy shares of TDOC?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Teladoc (TDOC) Stock Forecast & Price Target

TDOC Analyst Ratings

TDOC Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Teladoc

TDOC Analyst Recommendation Trends

TDOC Financial Forecast

TDOC Earnings Forecast

TDOC Sales Forecast

TDOC Stock Forecast FAQ

Detailed List of Analyst Forecasts